1.Carbamazepine caused severe drug eruption in treatment of tinnitus.
Hai-bo YANG ; Ding-qiang HUANG ; Yu-bo ZHU
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2012;47(3):248-249
Adult
;
Carbamazepine
;
adverse effects
;
therapeutic use
;
Drug Eruptions
;
etiology
;
Female
;
Humans
;
Tinnitus
;
drug therapy
2.Long-term Effectiveness and Tolerability of Topiramate in Children with Epilepsy under the Age of 2 Years: 4-Year Follow-up.
Jung Mi KIM ; Soonhak KWON ; Hye Eun SEO ; Byung Ho CHOE ; Min Hyun CHO ; Sung Pa PARK
Journal of Korean Medical Science 2009;24(6):1078-1082
This is a long-term, open label, observational study aimed to broaden our clinical experiences in managing infants and toddlers with epilepsy. The long-term retention rate and side effects of topiramate (TPM) in them were evaluated and compared with carbamazepine (CBZ). A total of 146 children were involved in the study (TPM=41, CBZ=105). The retention rates at 24 , 36, and 48 months were 46.3%, 34.1%, 26.8% for TPM and 36.2%, 23.8%, 13.3% for CBZ, respectively. At 6 months after starting antiepileptic drugs (AED), the seizure freedom or clinical efficacy (seizure reduction rate more than 50 percent) were 73.2% for TPM and 62.9% for CBZ. The major side effects led to discontinuation included psychomotor slowing, poor oral intake from TPM and sleepiness and skin rash from CBZ. TPM was discontinued due to side effects in one case (2.4%) and lack of efficacy in five cases (12.2%), whereas CBZ was discontinued due to lack of efficacy (22.9%) and side effects (6.7%). As compared with CBZ, TPM showed the same long-term retention rate in children under the age of 2 yr, and no serious side effects. It is therefore concluded that TPM can be considered as a major AED for treating children with epilepsy under the age of 2 yr.
Anticonvulsants/adverse effects/*therapeutic use
;
Carbamazepine/adverse effects/therapeutic use
;
Child
;
Child, Preschool
;
Epilepsy/*drug therapy
;
Female
;
Follow-Up Studies
;
Fructose/adverse effects/*analogs & derivatives/therapeutic use
;
Humans
;
Infant
;
Male
;
Treatment Outcome
3.Clinical efficacy of oxcarbazepine suspension in children with focal epilepsy.
Yin-Bo CHEN ; Yun-Peng HAO ; Xiao-Sheng HAO ; Dong LIANG
Chinese Journal of Contemporary Pediatrics 2013;15(5):340-342
OBJECTIVETo investigate the clinical efficacy and safety of oxcarbazepine (OXC) suspension in children with focal epilepsy.
METHODSA total of 118 children aged 2-14 years, who were newly diagnosed with focal epilepsy between October 2009 and December 2011, were randomly divided into experimental group (n=60) and control group (n=58). The experimental group was treated with an orally suspension of OXC and the control group was orally administered with carbamazepine (CBZ) tablets. The two treatment regimens were compared in terms of clinical efficacy and safety.
RESULTSAfter 13 and 26 weeks of treatment, the experimental group had response rates of 75% and 72% respectively and seizure-free rates of 53% and 50%, and the control group had response rates of 71% and 66% and seizure-free rates of 50% and 43% respectively. There were no significant differences in the clinical efficacy between the two groups (P>0.05). After 26 weeks of treatment, the adverse event rates of the experimental and control groups were 18% and 40% respectively, with a significant difference between the two groups (P<0.05).
CONCLUSIONSOXC suspension has a comparable clinical efficacy to that of CBZ tablets in children aged 2-14 years who are newly diagnosed with focal epilepsy, but OXC suspension causes fewer adverse events and has higher safety.
Adolescent ; Anticonvulsants ; therapeutic use ; Carbamazepine ; adverse effects ; analogs & derivatives ; therapeutic use ; Child ; Child, Preschool ; Epilepsies, Partial ; drug therapy ; Female ; Humans ; Male ; Suspensions
4.Effect of carbamazepine and valproate on bone metabolism in children with epilepsy.
Xiao-qing SONG ; Zhi-ping WANG ; Ke-rong BAO ; Jian-ming ZHANG ; Jie WU ; Chong-huai YAN ; Xiao-ming SHEN
Chinese Journal of Pediatrics 2005;43(10):728-732
OBJECTIVETo assess bone health in epileptic children who have been treated with carbamazepine (CBZ) or valproate (VPA) by using quantitative ultrasound (QUS) and determining the biochemical indices of bone metabolism, and to provide a proposal to improve quality of life of epileptic children.
METHODSNinety-two epileptic children who had been treated with CBZ or VPA for more than two years were evaluated for bone mineral density (BMD) at the mid-shaft tibia and the distal third of the radius. Biochemical indices of bone metabolism including urine deoxypyridinoline (DPD) and serum osteocalcin (OC), and daily calcium intake were also evaluated. Thirty-five age-matched healthy children were used as controls. Reduced BMD was defined as speed of sound (SOS) Z scores of the mid-shaft tibia and (or) the distal third of the radius less than -0.7.
RESULTSBMD was reduced in epileptic children significantly when compared to the controls (P < 0.05). In addition, a negative correlation was found between the duration of anti-epileptic drugs (AEDs) use and BMD (r(s) = -0.21 - -0.31, P < 0.05), the lowest BMD was observed in those who had been treated for the longest time. The serum values of OC in epileptic children were significantly reduced relative to the controls (P < 0.01), children who took VPA had the lowest value of OC. However, the urine values of DPD showed no significant difference between epileptic and healthy children (P > 0.05); children who took CBZ had the highest value of DPD. Thirty-two epileptic children (35%) and five (14%) sex- and age-matched healthy children had reduced BMD, significant difference was found between them (P < 0.05). Moreover, epileptic children with reduced BMD seemed to have higher body mass index (BMI) (P < 0.05), take less daily calcium intake (P < 0.01), and had longer duration of AEDs (P < 0.01). The two risk factors of having reduced BMD in epileptic children were those who had been treated with AEDs for more than five years and higher BMI, while the protective factor was daily calcium intake.
CONCLUSIONSLong-term use of CBZ or VPA is associated with bone metabolism abnormalities, which include reduced BMD and decreased bone turnover (mainly decreased bone formation). Long-term anti-epileptic therapy is an important factor for impaired bone health in epileptic children, and that low calcium intake and high BMI could be two aggravating factors. QUS is a useful method to evaluate BMD of epileptic children who are on long-term anti-epileptic therapy, and to recognize the status of bone health, in helping to promote bone health and improve quality of life in epileptic children by the use of calcium and vitamin D supplementation.
Amino Acids ; urine ; Anticonvulsants ; adverse effects ; therapeutic use ; Bone Density ; drug effects ; Bone and Bones ; diagnostic imaging ; drug effects ; metabolism ; Calcium, Dietary ; analysis ; Carbamazepine ; adverse effects ; therapeutic use ; Child ; Epilepsy ; drug therapy ; Female ; Humans ; Male ; Osteocalcin ; blood ; Radius ; diagnostic imaging ; Tibia ; diagnostic imaging ; Ultrasonography ; Valproic Acid ; adverse effects ; therapeutic use
5.Superficial siderosis of the central nervous system with seizures onset.
Chun-Yong CHEN ; Fang XIAO ; Jing-Li LIU
Singapore medical journal 2015;56(10):590-591
Ataxia
;
Carbamazepine
;
analogs & derivatives
;
therapeutic use
;
Carcinoma
;
Central Nervous System
;
pathology
;
Diagnosis, Differential
;
Female
;
Gait
;
Humans
;
Magnetic Resonance Imaging
;
Middle Aged
;
Nasopharyngeal Neoplasms
;
complications
;
radiotherapy
;
Nervous System Diseases
;
complications
;
diagnosis
;
Radiotherapy
;
adverse effects
;
Seizures
;
complications
;
diagnosis
;
Siderosis